CIK 0001395937 · Large accelerated filer
Syndax Pharmaceuticals Inc
Sign in to watch- Ticker
- SNDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 320162505
- Phone
- 781-419-1400
- Business address
- 730 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, 10017
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $113,716
- in 1 filing, $114K under 10b5-1 plans
Net −$113,716. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 25 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-03-01 | Morrison Briggs Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +200,000 | 200,000 | ||
| 2018-03-01 | Meyers Michael L. SVP, Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2018-03-01 | Metzger Michael A President and COO | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2018-02-08 | Podlesak Dennis Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2018-02-08 | Legault Pierre Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2018-02-08 | Katkin Keith Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2018-02-08 | EVNIN LUKE Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2018-02-08 | Egros Fabrice Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2018-02-08 | Chen Henry Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2017-05-17 | Ordentlich Peter Chief Scientific Officer | Option exercise | +732 | $3.08 | $2K | 5,000 |
| 2017-05-17 | Ordentlich Peter Chief Scientific Officer | Sale | −5,000 | $15.00 | $75K | 0 |
| 2017-05-17 | Ordentlich Peter Chief Scientific Officer | Option exercise · Employee Stock Option (right to buy) | −732 | 0 | ||
| 2017-05-17 | Sledge George W. Jr. Director | Grant or award · Stock Options (Right to buy) | +5,000 | 5,000 | ||
| 2017-05-17 | Podlesak Dennis Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2017-05-17 | Podlesak Dennis Director | Grant or award · Stock Option (Right to Buy) | +5,000 | 5,000 | ||
| 2017-05-17 | Legault Pierre Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2017-05-17 | Legault Pierre Director | Grant or award · Stock Option (Right to Buy) | +5,000 | 5,000 | ||
| 2017-05-17 | Katkin Keith Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2017-05-17 | EVNIN LUKE Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2017-05-17 | EVNIN LUKE Director | Grant or award · Stock Option (Right to Buy) | +5,000 | 5,000 |
Page 25 of 25 · 500 trades